The FDA's approval of $BIIB's Aduhelm is spurring major backlash in the scientific community — most notably, with the resignations of 3 advisers to the agency. The question now is whether lawmakers, payers and patients will balk. With @PamBelluck: https://t.co/DSzzLiNBtG
10
44
82
Replies
@RebeccaDRobbins @PamBelluck “Giving patients a drug that doesn’t work and of course has important risks that are going to require multiple MRIs at a price of $56,000 a year is putting patients in a really challenging position and putting doctors in a difficult position as well,” Dr. Kesselheim said.
0
3
6
@RebeccaDRobbins @nytimes @PamBelluck Defund the FDA! Stop their insanity!
0
0
0
@RebeccaDRobbins @PamBelluck It’s not a cure , failed two trials , will be given to patients while new trials are on - Aka patients are lab rats - and paying for it 56000 . That’s unethical.
1
0
2
@RebeccaDRobbins @PamBelluck After the advisory committee makes a reccomendation, who at the FDA actually approves the drug? Is it a committee or a single person? Is there a vote that is on record? Is there a way to investigate financial incentives?
0
0
2
@RebeccaDRobbins @nytimes @PamBelluck Paying $56,000 for a drug that doesn't work is worse than buying a car without an engine and wheels. Whoever approved this should be fired.
0
0
0